Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles -- Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy -- Monitoring Duchenne muscular dystrophy gene therapy with epitope-specific monoclonal antibodies -- Methods for noninvasive monitoring of muscle fiber survival with an AAV vector encoding the mSEAP reporter gene -- Monitoring murine skeletal muscle function for muscle gene therapy -- Phenotyping cardiac gene therapy in mice -- Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements -- Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy -- Systemic gene transfer to skeletal muscle using reengineered AAV vectors -- Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle -- Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy -- Application of microRNA in cardiac and skeletal muscle disease gene therapy -- Molecular imaging of RNA interference therapy targeting PHD2 for treatment of myocardial ischemia -- Lentiviral vector delivery of shRNA into cultured primary myogenic cells: A tool for therapeutic target validation -- Fetal muscle gene therapy/gene delivery in large animals -- Electroporation of plasmid DNA to swine muscle -- Local gene delivery and methods to control immune responses in muscles of normal and dystrophic dogs -- Gene transfer to muscle from the isolated regional circulation -- AAV-mediated gene therapy to the isolated limb in rhesus macaques -- Antisense oligo-mediated multiple exon skipping in a dog model of Duchenne muscular dystrophy -- Whole body skeletal muscle transduction in neonatal dogs with AAV-9 -- A translatable, closed recirculation system for AAV6 vector-mediated myocardial gene delivery in the large animal -- Method of gene delivery in large animal models of cardiovascular diseases -- Percutaneous transendocardial delivery of self-complementary adeno-associated virus 6 in the canine.